Introduction: Colorectal cancer (CRC) is the third most prevalent cancer globally, and metastatic CRC is almost always fatal. Early stages (0 to III) of CRC are generally curable, but Stage IV CRC is typically not curable and can only be controlled depending on the extent of disease spread. The objective of the current study is to discuss efficient targeted drug delivery systems for CRC and critically assess recent advancements in nanotechnology-based drug delivery. Methods: A critical review of the literature was conducted, including patent and clinical trial analyses on nanotechnology-based drug delivery systems for CRC. The research aimed to evaluate new nanocarriers such as dendrimers, liposomes, carbon nanotubes, and nanoemulsions. Results: Nanotechnology-based novel drug delivery systems were identified as more specific for targeting CRC cells. These technologies have been shown to exhibit greater cellular uptake, improved pharmacokinetics, and enhanced overall efficacy of anticancer drugs. Evidence from clinical trials and patent statistics reaffirms the potential of nanomedicines to revolutionize CRC therapy by increasing drug specificity and reducing systemic toxicity. Discussion: The findings indicate the enormous potential of nanotechnology to improve CRC therapy through better drug targeting and fewer side effects. The results are consistent with the growing body of literature supporting the integration of nanocarriers into oncology. Despite challenges such as the need for validation in clinical settings and the translation of laboratory successes into conventional medical practice, continued efforts are essential to make effective cancer treatment a reality without causing harm. Conclusion: Nanotechnology-based drug delivery systems have significant therapeutic potential in the management of CRC by maximizing treatment efficacy and minimizing side effects. Additional research and clinical data are needed to establish these systems as an integral part of routine clinical practice.
Dushyant et al. (Wed,) studied this question.